Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
ASCO Lung Cancer Highlights, Part 13: The Immune Checkpoint Inhibitor MPDL3280A in Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 12: Ganetespib with Second Line Chemotherapy for Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 11: Nintedanib with Second Line Chemotherapy for Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 10: Strategies After Resistance to Crizotinib in ALK-Positive Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 9: The MADeIT Study of Predictive Biomarkers for Chemotherapy in Advanced NSCLC (video)
ASCO Lung Cancer Highlights, Part 8: The Biomarkers France Study (video)
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (video)
ASCO Lung Cancer Highlights, Part 6: Predicting Benefit of Chemotherapy vs. EGFR Inhibitor Therapy in Second Line (video)
ASCO Lung Cancer Highlights, Part 5: Updates in Maintenance Therapy for Advanced NSCLC (video)
Dr. Rosalyn Juergens: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Greg Riely on "Which patients do you send molecular marker testing for, and what tests do you seek?"
ASCO Lung Cancer Highlights, Part 4: Exploring the Role of Trimodality Therapy for Stage III NSCLC (video)
ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC (video)
ASCO Lung Cancer Highlights, Part 2: Optimizing Radiation for Stage III NSCLC (video)
ASCO Lung Cancer Highlights, Part 1: Introduction to Stage III NSCLC (video)
Dr. Bob Doebele: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Dr. Philip Bonomi: Gefitinib and Later Generations of EGFR Inhibitors
Dr. David Spigel on "Which molecular marker tests do you seek?"
Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?
Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Create your
podcast in
minutes
It is Free
Good Mood Revolution
GRACEcast Pancreatic Cancer Audio
GRACEcast Radiation Oncology Audio
GRACEcast Head and Neck Cancer Video NEW
GRACEcast Kidney Cancer Video
GRACEcast Social Work and Coping Video